Clinical Trials | December 20, 2022
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Post the sale, Patel family has become the single largest promoter shareholder in the company
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Ayúdame3D has become a leading social entity in social technology.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Subscribe To Our Newsletter & Stay Updated
